Certificates Are Not Evidence: Regulators Target Product Identity and Strength

FDA issued a warning letter to Guangdong Bangze Medicine after a remote records review under section 704(a)(4). The review found reliance on unverified supplier certificates, no identity, assay or impurity testing of incoming components, incomplete finished-product testing and an ineffective quality unit; the facility’s products were already on Import Alert 66-40. In Australia, a New South Wales police investigation led TGA to test unapproved Synedica-branded peptide products: three contained no TB-500, and one contained less retatrutide than labelled, with large variation between samples. In the UK, MHRA issued a Class 3 recall for Tropicamide 1% Eye Drops over incorrect expiry labelling and a Class 4 defect notification for co-amoxiclav oral suspension over errors in the SmPC dosing table.

Regulators are treating supplier qualification, incoming testing, labelling and release as a single chain of accountability, in which a supplier CoA counts only if a documented qualification and periodic-verification system backs it. A weak link anywhere in that chain now leads quickly to import alerts, recalls or reputational damage.

Our Strategic Recommendation: Trace a sample of high-risk components end to end, from supplier qualification through receipt, identity testing and batch release. Confirm that any reduced testing is scientifically justified and that release systems block batches with missing results.

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangdong-bangze-medicine-co-ltd-734509-10262026

https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/tga-testing-finds-unapproved-peptides-do-not-contain-what-their-labels-claim

https://www.gov.uk/drug-device-alerts

BethAri can run this batch-trace challenge as part of a mock six-system audit.